Determination of key prognostic factors for the development of acne recurrence after systemic isotretinoin therapy
- Authors: Perlamutrov Y.N.1, Olhovskaya K.B.1, Solovyov A.M.1, Lyapon A.O.1
-
Affiliations:
- Yevdokimov Moscow State University of Medicine and Dentistry
- Issue: Vol 24, No 8 (2022)
- Pages: 529-533
- Section: Articles
- URL: https://ogarev-online.ru/2075-1753/article/view/112305
- DOI: https://doi.org/10.26442/20751753.2022.8.201753
- ID: 112305
Cite item
Full Text
Abstract
Since the 80s of the last century, the most effective drug for the treatment of acne is systemic isotretinoin (SI). The introduction of SI into practice makes it possible to achieve stable clinical remission or complete recovery in 80% of acne patients, regardless of the severity of the disease, however, 20% of patients may experience relapses in the next 1.5–2 years.
Aim. To establish the factors determining the likelihood of acne recurrence after a course of therapy using the systemic isotrtinoin.
Materials and methods. After examining 275 patients, 84 patients (50 women and 34 men) who had previously been treated with SI for acne took part in the study, 54 of them had relapses for at least 4 months and the comparison group consisted of 30 patients out of 221 surveyed who did not have relapses after treatment. As part of the study, a retrospective analysis of outpatient records was carried out, data on the history of life and illness, comorbid hormonal pathology in women, anthropometric characteristics were recorded, and the presence of heredity for acne was also taken into account, the severity of acne was assessed using the Investigator's Global Assessment scale; laboratory examination was performed to exclude insulin resistance.
Results. The development of relapses after the first course of acne treatment using SI was registered in 19.63%, however, indications for a second course of treatment were stated in 12.00%. The analysis of the data obtained allowed us to determine the main factors that contributed to the development of relapses: severe acne severity, the presence of rashes on the trunk, body mass index more than 25, the presence of hormonal abnormalities in women, scarification, male sex, daily dose less than 0.5 mg/kg, the presence of heredity for acne in both parents, the course dose of SI<120 mg/kg, insulin resistance.
Conclusion. The issue of studying the factors that can cause the development of acne recurrence after the end of the course of therapy is an extremely urgent problem, due to the fact that taking them into account at the early stages of treatment of patients will increase the percentage of patients with complete clinical remission or recovery.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Yuri N. Perlamutrov
Yevdokimov Moscow State University of Medicine and Dentistry
Email: y.perlamutrov@mail.ru
ORCID iD: 0000-0002-4837-8489
D. Sci. (Med.), Prof.
Russian Federation, MoscowKira B. Olhovskaya
Yevdokimov Moscow State University of Medicine and Dentistry
Author for correspondence.
Email: olhovskaya_kira@mail.ru
ORCID iD: 0000-0003-4920-5288
Cand. Sci. (Med.)
Russian Federation, MoscowAnton M. Solovyov
Yevdokimov Moscow State University of Medicine and Dentistry
Email: doctorsolovyov@mail.ru
ORCID iD: 0000-0003-3113-8929
Cand. Sci. (Med.)
Russian Federation, MoscowAlexandra O. Lyapon
Yevdokimov Moscow State University of Medicine and Dentistry
Email: aolkafedra@mail.ru
ORCID iD: 0000-0002-7762-6410
Cand. Sci. (Med.)
Russian Federation, MoscowReferences
- Монахов СА. Радикальная терапия акне. Клиническая дерматология и венерология. 2012;10(1):39-48 [Monakhov SA. Radical therapy of acne. Klinicheskaya Dermatologiya i Venerologiya. 2012;10(1):39-48 (in Russian)].
- Dréno B, Pécastaings S, Corvec S, et al. Cutibacterium acnes (Propionibacterium acnes) and acne vulgaris: a brief look at the latest updates. J Eur Acad Dermatol Venereol. 2018;32(Suppl. 2):5-14. doi: 10.1111/jdv.15043
- Thiboutot DM, Dréno B, Abanmi A, et al. Practical management of acne for clinicians: An international consensus from the Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2018;78(2 Suppl. 1):S1-23.e1. doi: 10.1016/j.jaad.2017.09.078
- Thiboutot D, Dréno B, Sanders V, et al. Changes in the management of acne: 2009–2019. J Am Acad Dermatol. 2020;82(5):1268-9. doi: 10.1016/j.jaad.2019.04.012
- Смирнова И.О., Петунова Я.Г., Куликова Е.А., Еремеева А.С. Изотретиноин: эффективность и безопасность. Клиническая дерматология и венерология. 2015;14(6):20-7 [Smirnova IO, Petunova IaG, Kulikova EA, Eremeeva AS. Isotretinoin: efficacy and safety (literature review). Klinicheskaya Dermatologiya I Venerologiya. 2015;14(6):20-7 (in Russian)]. doi: 10.17116/klinderma201514620-27
- Bettoli V, Guerra-Tapia A, Herane MI, Piquero-Martín J. Challenges and Solutions in Oral Isotretinoin in Acne: Reflections on 35 Years of Experience. Clin Cosmet Investig Dermatol. 2019;12:943-51. doi: 10.2147/CCID.S234231
- Самгин М.А., Монахов С.А. Акне (лекция). Российский журнал кожных и венерических болезней. 2005;3:45-52 [Samgin MA, Monakhov SA. Akne (a lecture). Russian Journal of Skin and Venereal Diseases. 2005;3:45-52 (in Russian)].
- Dessinioti C, Zouboulis CC, Bettoli V, Rigopoulos D. Comparison of guidelines and consensus articles on the management of patients with acne with oral isotretinoin. J Eur Acad Dermatol Venereol. 2020;34(10):2229-40. doi: 10.1111/jdv.16430
- Saadet ED. Investigation of relapse rate and factors affecting relapse after oral isotretinoin treatment in patients with acne vulgaris. Dermatol Ther. 2021;34(6):e15109. doi: 10.1111/dth.15109
- Fallah H, Rademaker M. Isotretinoin in the management of acne vulgaris: practical prescribing. Int J Dermatol. 2021;60(4):451-60. doi: 10.1111/ijd.15089
- Перламутров Ю.Н., Ольховская К.Б. Клиническая эффективность и профиль безопасности системного изотретиноина в терапии акне. Клиническая дерматология и венерология. 2020;19(5):730-6 [Perlamutrov YuN, Olkhovskaya KB. Clinical effectiveness and safety profile of systemic isotretinoin in acne therapy. Klinicheskaya Dermatologiya i Venerologiya. 2020;19(5):730-6 (in Russian)]. doi: 10.17116/klinderma202019051730
- Кохан М.М., Кениксфест Ю.В., Шайбакова Ю.Б., и др. Эффективность и безопасность терапии больных акне с применением системного изотретиноина: доказательные данные и клинический опыт. РМЖ. 2015;23(19):1150-4 [Kokhan MM, Keniksfest YuV, Shaibakova IuB, et al. Effektivnost` i bezopasnost` terapii bol`nykh akne s primeneniem sistemnogo izotretinoina: dokazatel`ny`e danny`e i klinicheskii opy`t. Rossiiskii meditsinskii zhurnal. 2015;23(19):1150-4 (in Russian)].
Supplementary files
